Nektar Therapeutics
NKTR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $98 | $90 | $92 | $102 |
| % Growth | 9.2% | -2.1% | -9.7% | – |
| Cost of Goods Sold | $31 | $37 | $22 | $25 |
| Gross Profit | $68 | $53 | $70 | $77 |
| % Margin | 68.8% | 59.3% | 76.5% | 75.6% |
| R&D Expenses | $121 | $114 | $218 | $400 |
| G&A Expenses | $77 | $77 | $92 | $123 |
| SG&A Expenses | $77 | $77 | $92 | $123 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$25 | -$1 | $0 | $0 |
| Operating Expenses | $173 | $191 | $311 | $523 |
| Operating Income | -$105 | -$137 | -$240 | -$446 |
| % Margin | -106.9% | -152.5% | -261% | -437.8% |
| Other Income/Exp. Net | -$14 | -$139 | -$125 | -$77 |
| Pre-Tax Income | -$119 | -$276 | -$365 | -$523 |
| Tax Expense | -$0 | -$0 | $3 | $1 |
| Net Income | -$119 | -$276 | -$368 | -$524 |
| % Margin | -120.9% | -306.3% | -400% | -514% |
| EPS | -8.68 | -21.79 | -29.51 | -42.9 |
| % Growth | 60.2% | 26.2% | 31.2% | – |
| EPS Diluted | -8.68 | -21.79 | -29.51 | -42.9 |
| Weighted Avg Shares Out | 14 | 13 | 12 | 12 |
| Weighted Avg Shares Out Dil | 14 | 13 | 12 | 12 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15 | $19 | $7 | $3 |
| Interest Expense | $28 | $25 | $29 | $47 |
| Depreciation & Amortization | $4 | $8 | $12 | $14 |
| EBITDA | -$87 | -$243 | -$324 | -$462 |
| % Margin | -88.1% | -269.8% | -351.8% | -453.2% |